Person: KARAHASAN, AYŞEGÜL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARAHASAN
First Name
AYŞEGÜL
Name
13 results
Search Results
Now showing 1 - 10 of 13
Publication Metadata only Sağlıklı çocukların orafarenksinde kolonize olan bakteriyel patojenlerin antimikrobiyal duyarlılıkları(Ankara Üniversitesi Tıp Fakültesi Yayınları, 2000-10-11) KARAHASAN, AYŞEGÜL; İLKİ, ZEYNEP ARZU; ÜLGER, NURVER; SÖYLEDİR, GÜNER; Karahasan A., İlki Z. A., Ülger N., Söyledir G.; Cengiz, A. Tevfik; Erdem, Birsel; Dolapçı, G. İştar; Tekeli, F. AlperPublication Open Access Evaluation of BioFire Filmarray panel for respiratory pathogens: A demographic and clinical analysis in Istanbul, Turkey(2023-05-01) KARAHASAN, AYŞEGÜL; ÇİMŞİT, NURİ ÇAGATAY; Karahasan A., Çimşit N. Ç.We aimed to analyze the distribution of respiratory pathogens(RP) detected by a multiplex PCR-based method (BioFire Diagnostics, USA) among patients with suspected respiratory tract infections (RTI) and to evaluate the demographic, clinical and radiological characteristics of infected individuals . RP were detected in 1621/6376 (25.4%) of the samples in the years 2018-2020. Rhinovirus/enterovirus (RV/EV) were the most commonly detected pathogens (38.1%) followed by influenza A and B viruses (21%) and parainfluenza virus (PIV) (9.5%). Single pathogen was detected in 1361 (84%) and multi pathogens in 260 (16%) of 1621 samples. At least one comorbidity was present in 379 (30.5%) of the patients. Fever was the most common sign followed by cough and dyspnea. Thorax CT was present in 426 of 1243 RP positive patients (34.3%). Any radiological findings was found significantly related for a specific pathogen. No medication was given to 52.9% whereas antibiotics in 35.7% and antivirals in 3.8% of the patients. Film Array panel as a multiplex PCR test is not used rationally in our hospital and results were not dramatically improve management of RTI. A better communication between clinician and microbiologist is required for efficient use of laboratory and rational use of antimicrobials.Publication Metadata only Polimeraz zincir reaksiyonu temelli tiplendirme yöntemleri: AP-PCR, ERIC-PCR, REP-PCR, PCR-RFLP(Nobel Yayın Dağıtım, 2022-11-01) KARAHASAN, AYŞEGÜL; Karahasan A.; Otlu, Barış; Durmaz, RızaPublication Metadata only İdrar kültürlerinde kontaminasyon oranları düşürülebilir mi(2023-05-01) KARAHASAN, AYŞEGÜL; Karahasan A.Publication Open Access Demographic features and laboratory parameters among hospitalized vaccinated patients with covid-19 in Istanbul, Turkey(2023-05-01) KARAHASAN, AYŞEGÜL; Karahasan A.BackgroundThe number ofCOVID-19cases has been decreasing recently, and the restrictions are waived in many countries. The data aboutvaccineefficacy are essential to be prepared for the future even if the pandemic ends and the disease becomes endemic.AimsThe aim of this study was to define demographic and laboratory data for disease severity among vaccinatedCOVID-19cases who were hospitalized.Study DesignThis is a retrospective cohort study.MethodsSARS-CoV-2 polymerase chain reaction–positive patients who were fully vaccinated (2 doses of vaccines and 3 doses of vaccines) and had been hospitalized at least 15 days after the lastvaccinedose were enrolled in this study. Patients\" data including laboratory parameters were retrieved, and descriptive statistics and comparison of variables were calculated.ResultsBetween September 1, 2021, and February 28, 2022, 685 patients (mean age, 67.84 years; 50.8% female) were hospitalized. Inactivated whole-virion SARS-CoV-2vaccine(CoronaVac) had been administered to 467 of the patients (68.4%), BNT162b2 mRNAvaccine(Pfizer-Pfizer-BioNTech) had been administered to 107 of the patients (15.6%), and to 111 of the patients (16%), a combination of 2 vaccines had been administered. At least 1 comorbidity was present in 160 participants (23%) and more than 4 comorbidities in 46 patients (6.6%). The most common comorbidity was hypertension (349, 50.2%). The presence of comorbidities was significantly higher in patients having 3 doses ofvaccine. Increased ferritin levels were determined in 56.4% of the patients, increased D-dimer levels in 69.9% of the patients, increased C-reactive protein levels in 79.7% of the patients, and increased procalcitonin levels in 61.5% of the patients. A total of 36.4% of the patients had decreased lymphocyte counts, 20% had low lymphocyte/monocyte ratio, and 22% had decreased neutrophil/lymphocyte ratio. The only parameter that was significantly higher in patients having 3vaccinedoses was procalcitonin. Mean duration of hospitalization was 9.68 ± 7.29 days. In the CoronaVac and Pfizer-BioNTech groups, 68.5% and 21.4%, respectively, of the patients were older than 65 years. Seventeen (3.6%) patients in the CoronaVac group, 6 (5.4%) patients in the combination group, and 3 (2.8%) patients in Pfizer-BioNTech group had been admitted to the intensive care unit. Mortality rate was 0.3% (2 of 685 patients).ConclusionsThe incidence of severeCOVID-19disease among fully vaccinated patients is low even in the presence of comorbidities, older age, and presence of abnormal laboratory parameters, regardless of thevaccinetype.Publication Open Access Molecular analysis of human adenoviral keratoconjunctivitis cases: Results of a 2-year survey(2023-01-01) KARAHASAN, AYŞEGÜL; Karahasan A.Publication Open Access The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells(2022-04-01) HAKLAR, GONCAGÜL; KARAHASAN, AYŞEGÜL; DURMUŞOĞLU, LÜTFİYE; Bilgin H., Marku M., Yilmaz S. S., Karahasan Yagci A., Sili U., Can B., Can Sarinoglu R., Mulazimoglu Durmusoglu L., Haklar G., Sirikci O., et al.Objectives: We evaluated the antibody response, natural killer cell response and B cell phenotypes in healthcare workers (HCW) who are vaccinated with two doses of CoronaVac with or without documented SARS-CoV-2 infection and unvaccinated HCWs with SARS-CoV-2 infection. Methods: HCWs were divided into four groups: vaccine only (VO), vaccine after SARS-CoV-2 infection (VAI), SARS-CoV-2 infection only (IO), and SARS-CoV-2 infection after vaccine (IAV). Anti-SARS-CoV-2 spike protein (Anti-S) antibodies were measured by Elecsys Anti–SARS–CoV–2 S ELISA kit. Memory B cells (CD19+ CD27+ ), plasmablast B cells (CD19+ CD138+ ) and long-lived plasma cells (LLPC; CD138+ CD19- ) were measured by flow cytometry in 74 patients. Interferon gamma (IFN-c) release by natural killer (NK) cells were measured by NKVue Test (NKMAX, Republic of Korea) in 76 patients. RT-PCR was performed with Bio-speedy COVID-19 qPCR detection kit, Version 2 (Bioexen LTD, Istanbul, Turkey). Results: The Anti-S antibodies were detectable in all HCWs (n: 224). The median Anti-S titers (BAU/mL) was significantly higher in VAI (620 25–75% 373–1341) compared to VO (136, 25–75% 85–283) and IO (111, 25–75% 54–413, p < 0.01). VAI group had significantly lower percentage of plasmablasts (2.9; 0– 8.7) compared to VO (6.8; 3.5–12.0) and IO (9.9; 4.7–47.5, p < 0.01) (n:74). Percentage of LLPCs in groups VO, VAI and IO was similar. There was no difference of IFN-c levels between the study groups (n: 76). Conclusion: The antibody response was similar between uninfected vaccinated HCWs and unvaccinated HCWs who had natural infection. HCWs who had two doses of CoronaVac either before or after the natural SARS-CoV-2 infection elicited significantly higher antibody responses compared to uninfected vaccinated HCWs. The lower percentages of plasmablasts in the VAI group may indicate their migration to lymph nodes and initiation of the germinal center reaction phase. IFN-c response did not differ among the groups.Publication Open Access COVID-19 disease characteristics in different pediatric age groups(2022-01-01) ŞENYÜREK, BETÜL; BORAN, PERRAN; KEPENEKLİ KADAYİFCİ, EDA; YAKUT, NURHAYAT; KARAHASAN, AYŞEGÜL; AYDINER, ELİF; MEMİŞOĞLU, ASLI; GÖKDEMİR, YASEMİN; ERDEM ERALP, ELA; KARADAĞ, BÜLENT TANER; KEPENEKLİ KADAYİFCİ E., YAKUT N., Ergenc Z., Aydiner O., Sarinoglu R. C., KARAHASAN A., Karakoc-Aydiner E., MEMİŞOĞLU A., GÖKDEMİR Y., ERDEM ERALP E., et al.Introduction: Little is known about the COVID-19 disease characteristics and differences between different pediatric age groups. This study aimed to investigate the disease characteristics according to age groups. Methodology: We conducted a retrospective, single-center study of pediatric COVID-19 in a tertiary care hospital in Turkey. The patients were divided into three groups: 15 days-24 months old (Group 1), 25-144 months old (Group 2), and 145-210 months old (Group 3) according to age. Results: A total of 139 pediatric patients with COVID-19 were examined. Twenty-nine patients (20.9%) were in Group 1, 52 (37.4%) were in Group 2, 58 (41.7%) were in Group 3. Thirty-nine patients (28.1%) were hospitalized. The most common symptoms were cough (55.4%) and fever (51.8%). The median chest X-ray (CXR) score of hospitalized patients was 1 (min 0-max 7), and the median CXR score of outpatients was 1 (min 0-max 6). Fever was significantly more frequent in Group 1, and chest pain was more frequent in Group 3. Group 1 had significantly higher WBC, lymphocyte, thrombocyte counts, AST, LDH, D-dimer, and Troponin T levels but lower hemoglobin, total protein, and albumin levels. The treatment included antibiotics, oseltamivir, hydroxychloroquine, and supportive therapy. Only one patient (0.7%) received noninvasive mechanical ventilatory support. Conclusions: As we know the clinical course of COVID-19 in children is less severe than in adults. We also found significant differences in both clinical and laboratory findings between different pediatric age groups which supports the theory that disease pathogenesis is highly variable according to age.Publication Metadata only Menenjit paneli test sonuçlarının değerlendirilmesi: 2022 yılı analizi(2023-11-02) ÜLGER, NURVER; İLKİ, ZEYNEP ARZU; KARAHASAN, AYŞEGÜL; Demirkol Ö., Ülger N., İlki Z. A., Karahasan A.Publication Open Access Retrospective analysis of serology and radiology results in patients with suspected cystic echinococcosis through 3 years period(2023-05-01) KARAHASAN, AYŞEGÜL; Karahasan A.Objective: Cystic echinococcosis (CE), caused by the larval stage of Echinococcus granulosus sensu latu, is one of the neglected zoonotic infectious diseases and Türkiye is among the endemic countries. This study was designed to analyze serology results for patients who were diagnosed as CE by clinical symptoms and radiological methods over a three-year period. Methods: Sera were analyzed for Anti-E. granulosus IgG by a chemiluminescence immunoassay (CLIA) (HYDATIDOSIS VIRCLIA® IgG MONOTEST, Vircell) using the VIRCLIA® (CLIA; Vircell, Granada, Spain) and results processed by the dedicated software. Cutoff for a positive test was ≥1.1 index value. Echinococcal cysts were detected based on ultrasonography, computed tomography, and magnetic resonance imaging. Results: A total of 244 sera were analyzed from 109 patients, during three-year-period from January 2018 to December 2020. Anti-E. granulosus IgG was ordered twice in 89 patients, three times in 15 patients, four times in four patients, and five times in one patient. CLIA test was positive among 41 of 109 (37.6%) patients in whom 32 (76%) had only hepatic involvement, whereas in 5 (12%) hepatic and pulmonary involvement were coexisted. The mean age of seropositive patients was 39.8 (6-75±2.72) and 61.9% of them (n=26) were female. Time intervals between sequential test orders varied from 1 day to 33 months. Eight seropositive patients turned out to be negative, and one of 66 seronegative patients became seropositive. Positive test results were converted to negative in the case of therapy or cyst inactivit